LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

Inicio・Lista de Acciones・CareDx Inc

CareDx Inc

Abierto

SectorSanidad

20.89 0.58

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.32

Máximo

21.1

Métricas clave
By Trading Economics
Ingresos	6.9M 2.8M
Ventas	9.3M 118M
P/B Media del Sector	14.645 51.415
BPA	0.34
Margen de beneficios	2.387
Empleados	761
EBITDA	5.6M 7.1M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+15.56% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-5.8M 1.1B
Apertura anterior	20.31
Cierre anterior	20.89

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

12 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

14.77 / 18.49 Soporte y Resistencia

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2026, 22:54 UTC

Ganancias

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 may 2026, 23:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2026, 23:51 UTC

Charlas de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 may 2026, 23:17 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 may 2026, 23:16 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 may 2026, 23:15 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 may 2026, 23:14 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 may 2026, 23:02 UTC

Charlas de Mercado

Ganancias

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 may 2026, 22:59 UTC

Charlas de Mercado

Ganancias

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 may 2026, 22:24 UTC

Ganancias

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Revenue Growth 47%>XRO.AU

13 may 2026, 22:22 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 may 2026, 22:18 UTC

Ganancias

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 may 2026, 22:16 UTC

Ganancias

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 may 2026, 22:13 UTC

Ganancias

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 may 2026, 22:12 UTC

Ganancias

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 may 2026, 22:09 UTC

Ganancias

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 may 2026, 22:00 UTC

Ganancias

Cisco to Shed Jobs for All-In AI Push -- Update

13 may 2026, 21:11 UTC

Ganancias

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

15.56% repunte

Estimación a 12 Meses

Media 24.73 USD 15.56%

Máximo 28 USD

Mínimo 21 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para CareDx Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

The bullish and bearish events are balanced.

All events are bearish.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

12 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.